At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 100 target
Drug / intervention
single dose of CNCT19biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04684147Phase 2RecruitingUpdate OverdueUpdated 10mo ago · Completion was 45mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating single dose of CNCT19 for Relapsed or Refractory Acute Lymphoblastic Leukemia. Currently recruiting, targeting 100 participants across 11 sites.
Signals
Enrollment appears stalled
Detailed Summary
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2021202220232024202520262027
First PostedDec 2020
Enrollment StartDec 2020
Primary CompletionSep 2022
TodayJul 2026
Study CompletionDec 2026
First PostedDec 24, 2020
Enrollment StartDec 24, 2020
Primary CompletionSep 22, 2022
Study CompletionDec 31, 2026
TodayJul 1, 2026
Enrollment to primary: 1.7 yearsPosted 5.5 years ago
Interventions
single dose of CNCT19biological
Dose: 0.5 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide